The latest report on Japan's biopharmaceutical market, including market size and growth projections, has been published. The market is projected to be valued at US$12.20 billion in 2025 and reach US$22.90 billion by 2035, with a projected CAGR of 6.5%.
Japan's biopharmaceutical market is projected to reach US$12.20 billion in 2025 and expand at a CAGR of 6.5% from 2026 to 2035. Growth drivers include rising demand for targeted treatments for cancer and autoimmune diseases, government support for regenerative medicine and gene therapy, the wider adoption of biosimilars, and expanded domestic biomanufacturing capacity.
By indication, oncology is expected to account for the largest share, with multiple categories, including monoclonal antibodies, CAR-T therapies, and gene therapies, supporting market expansion. In the immunology segment, biologics are becoming more widely used, while biosimilars may play a more important role because of treatment-cost concerns.
On the supply side, the expansion of domestic biomanufacturing capacity is emphasized as a prerequisite for market growth, and plans for a new manufacturing facility in Yokohama were announced in May 2025. Cell and gene therapies require advanced production systems, and the development of domestic CDMOs, logistics networks, and hospital infrastructure is also expected to contribute to growth.